For the past decade, global investment in biomedical research, both basic and clinical, has surged forward. The United States doubled the budget of the National Institutes of Health (NIH) between 1998 and 2003, and many other governments have eagerly supported the life sciences, sometimes at the expense of other areas of research.
But in October 2008, the banking system collapsed and knocked the stuffing out of government balance sheets. Since then, eagerness for funding biomedical research has stalled. And, according to analysts and senior researchers in the fifteen largest scientific powers, funding will go into reverse during 2011. With stories of deep cuts circulating, the atmosphere in many labs is one of alarm.
However, a closer look at budget plans shows that governments aren't axing spending, but rather retrenching. In fact, most nations are protecting science from steeper cuts applied to other areas of public spending. The United States, which utterly dominates global spending on biomedical research, and Britain, which has energetically sought leadership in some areas of it, will each try to maintain spending at 2010 levels this year, even in the face of huge budgetary pressures.
That said, some mid-sized players, including Italy, Spain, Canada, and Australia, have already cut back their spending since 2008. And Singapore is sharply reorientating its program by diverting 30% of its planned biomedical research spending to partnerships with industry. Other nations are pressing their researchers to generate visible results, fast.
But the frigid funding outlook isn't global. Scientific powers with strong export industries have been protected from the spending slump, as China, Korea, India, and Germany are planning substantial increases in the spending on biomedical research for 2011.
Apples and Oranges
International comparisons of health research spending are notoriously difficult. Most nations lack a dominant agency akin to the US's NIH, supporting both laboratory and clinical research. Many nations pay researchers' salaries out of nonresearch budgets, and their basic research efforts aren't easily allocated to specific missions, such as health. Thus, the world's main repositories of research statistics-the OECD (Organisation for European Economic Cooperation) in Paris, Eurostat in Luxembourg, and the US National Science Foundation in Arlington, Virginia-struggle to agree on what constitutes health research spending.
Nevertheless, spending on biomedical research is heavily skewed toward wealthy countries in general and the US in particular. According to an exhaustive 2007 study by the European Medical Research Councils, the US spends $40 billion annually. This is 2-3 times as much as the European Union, which in turn spends significantly more than the rest of the world combined.
But could this balance of power be shifting? A rapid-fire global tour of the world's largest spenders reveals the beginnings of a swing in government spending on biomedical research, with investments in Asia surging forward, although admittedly from a low base.
2012-NIH's Year of Reckoning
The outlook for the United States typifies the global picture in developed countries. Although the current financial year for the US began in October 2010, Congress isn't expected to complete the 2011 budget until this March. Until then, spending is frozen at last year's level of $31 billion, and any adjustment is likely to be downwards. The newly elected House of Representatives, now under the Republican's control, will try to cut the budget, perhaps by $2 billion, and the biomedical research lobby will be looking to its allies in the Senate to protect it.
This means that, in the most optimistic scenario, the actual value of the NIH budget will fall by 3% in 2011, once inflation is taken into account. Obama will propose his budget for 2012 this February, before the 2011 budget is even complete, and Congress is again expected to try and reduce whatever number he proposes. Every nation's research budget has its quirks, and the biggest one for the US Funding in Australia also grew quickly over the last decade. However, the budget for the National Health and Medical Research Council in Australia peaked at AU $714 million in 2009, and it has been frozen ever since. ''The outlook for next year looks bleak,'' says Julie Campbell, a biologist at the University of Queensland and president of the Association of Australian Medical Research Institutes. ''There certainly is no hope for an increase, with a real threat that it may be decreased.''
Asia Surges Forward
In Asia, the picture is quite different. Korea's spending in areas related to biotechnology powered ahead from less than US $100 million in 1998 to $850 million in 2008 and $1.25 billion in 2010. This money comes from three separate government departments and goes to both basic and clinical research. According to researchers and government officials, Korea's funding will probably keep growing at a compound rate of around 20%.
India has experienced a massive boom in private-sector research and development since 2005, when it transformed its large pharmaceutical industry by reforming its patent laws. Moreover, the Indian government is preparing to increase the combined budget for its biotechnology and science departments (US $700 million) by more than 20% this year.
China's budgets are notoriously opaque, and details of its research spending don't feature in the OECD's international comparisons.
Nonetheless, China's biomedical spending has been growing relentlessly, probably close to the annual compound rate that the Chinese report for research and development-an impressive 22.6% per year.
Yet China's efforts have to be kept in perspective. From 2006-2008, for example, China spent just 11.9 billion Yuan (US $1.8 billion) on research aimed at health and agriculture combined (see UNESCO report). Assuming China invests the same again on other basic research related to health, this puts China's investment in biomedical research just above Korea's and still considerably below that of Japan.
Early last month, Reuters published an unconfirmed report that China might invest an astounding $1.5 trillion dollars in seven high-tech industry sectorsincluding biotechnology-under its five year plan for 2011-2015. Such leaks are used habitually in China to signal intent rather than to plan budgets. And, in the past, China has put agriculture ahead of health as a biotechnology priority. Nonetheless, the announcement offers a taste of what could lie ahead if China's economy continues to expand.
Perhaps the world's most audacious experiment in building a biomedical research hub from scratch has taken place in Singapore. In 2000, Singapore established the BioMedical Research Council (BMRC), which offered large, unfettered grants for basic research. This strategy has developed a significant research capability, drawing significant global attention and attracting a large number of talented scientists in areas such as stem cell research. However, in September 2010, the government announced that its approach will change. The amount of money available for biomedical research will grow slightly in 2011-2015, to SI $3.7 billion (US $2.8 billion), but 30% of that will be available only for collaborations with drug companies.
''The money will be distributed in a different way,'' says George Radda, chair of the BMRC. ''The government is expecting researchers to show some returns for its investment.'' The priority shift came after a governmental study found that investments in engineering research provided stronger economic returns for Singapore. ''The principles are not bad,'' comments one leading biologist in Singapore. ''But the execution will be a challenge.'' Japanese public spending on biomedical research, which is split between several agencies, has grown slowly over the past decade. Now it totals about 340 billion yen (US $4 billion). Its 2011 budget hadn't been agreed at the time of writing, but it was expected to be flat or slightly down, according to analysts in Japan.
Deutsche Boom, Euro Gloom Of the major European nations, only Germany is planning a significant expansion for biomedical funding in 2011. The science ministry will increase funding by 7%, and an additional V300 million is allocated to translational work. So the total biomedical budget could grow by as much as 11% in 2011.
France has also backed the life sciences over the last few years, though less emphatically than Germany. French politicians traded barbs last October over whether the total 2011 research budget across all agencies was actually up or down. But, nevertheless, the main biomedical agency in France, Inserm, will receive a 4.3% funding increase this year.
After taking a swinging 14% cut last year, Spanish researchers are breathing a small sigh of relief in 2011-their science and innovation ministry is being protected from an austerity budget now pushing through the legislature. But the atmosphere in universities in southern Europe is still downbeat. Like colleagues in Italy, who experienced double-digit cuts across all disciplines last year, Spanish researchers are worried that their prospects of catching up with neighbors in northern Europe are receding, perhaps for good. ''The situation in Italy is dismal,'' says Ramon Marimon, a former Spanish science secretary currently working as an economist in Florence, ''and it has been for some time.''
In conclusion, nations whose economies have held up since the 2008 financial crisis may be rewarded in 2011 with an opportunity to make inroads into the established biomedical order. If Asia's economic resurgence and scientific renaissance continue, a real change in the global balance of power in biomedical research could indeed transpire. But these future scientific powerhouses still have a lot of ground to cover to approach the funding levels of the United States.
